DK1370556T3 - Metalloproteinaseinhibitorer - Google Patents

Metalloproteinaseinhibitorer

Info

Publication number
DK1370556T3
DK1370556T3 DK02704031T DK02704031T DK1370556T3 DK 1370556 T3 DK1370556 T3 DK 1370556T3 DK 02704031 T DK02704031 T DK 02704031T DK 02704031 T DK02704031 T DK 02704031T DK 1370556 T3 DK1370556 T3 DK 1370556T3
Authority
DK
Denmark
Prior art keywords
metalloproteinase
Prior art date
Application number
DK02704031T
Other languages
Danish (da)
English (en)
Inventor
Anders Eriksson
Matti Lepistoe
Michael Lundkvist
Af Rosenschoeld Magnus Munck
Pavol Zlatoidsky
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1370556T3 publication Critical patent/DK1370556T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DK02704031T 2001-03-15 2002-03-13 Metalloproteinaseinhibitorer DK1370556T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100902A SE0100902D0 (sv) 2001-03-15 2001-03-15 Compounds

Publications (1)

Publication Number Publication Date
DK1370556T3 true DK1370556T3 (da) 2006-10-30

Family

ID=20283374

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02704031T DK1370556T3 (da) 2001-03-15 2002-03-13 Metalloproteinaseinhibitorer

Country Status (33)

Country Link
US (8) US7427631B2 (hu)
EP (4) EP1370556B1 (hu)
JP (4) JP4390457B2 (hu)
KR (4) KR100886315B1 (hu)
CN (5) CN100526307C (hu)
AR (2) AR035695A1 (hu)
AT (3) ATE484496T1 (hu)
AU (2) AU2002237632B2 (hu)
BR (3) BR0207984A (hu)
CA (3) CA2440473C (hu)
CY (1) CY1107525T1 (hu)
CZ (3) CZ20032500A3 (hu)
DE (3) DE60238794D1 (hu)
DK (1) DK1370556T3 (hu)
EE (3) EE05364B1 (hu)
ES (3) ES2267986T3 (hu)
HK (3) HK1091492A1 (hu)
HU (3) HUP0400327A3 (hu)
IL (5) IL157657A0 (hu)
IS (3) IS6942A (hu)
MX (3) MXPA03008177A (hu)
MY (2) MY136141A (hu)
NO (3) NO326087B1 (hu)
NZ (3) NZ528107A (hu)
PL (3) PL364707A1 (hu)
PT (1) PT1370556E (hu)
RU (3) RU2285695C2 (hu)
SE (1) SE0100902D0 (hu)
SI (1) SI1370556T1 (hu)
SK (3) SK287834B6 (hu)
UA (3) UA77667C2 (hu)
WO (3) WO2002074748A1 (hu)
ZA (4) ZA200306734B (hu)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202693D0 (sv) * 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
AU2003282920A1 (en) * 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
JP4866610B2 (ja) 2003-08-18 2012-02-01 富士フイルムファインケミカルズ株式会社 ピリジルテトラヒドロピリジン類およびピリジルピペリジン類
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
JP2008512463A (ja) * 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP2289510A1 (en) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
MX2007011378A (es) * 2005-03-16 2008-03-18 Sensus Metering Systems Inc Metodo, sistema, aparato y producto de programa de computadora para determinar la ubicacion fisica de un sensor.
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
EP1968961A2 (en) * 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
PE20071240A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
WO2007133128A1 (en) * 2006-05-12 2007-11-22 Sca Hygiene Products Ab Elastic laminate and a method for producing an elastic laminate
MX2008014154A (es) * 2006-05-12 2008-11-18 Sca Hygiene Prod Ab Articulo absorbente del tipo de calzoncillos y un metodo para producir articulos absorbentes de tipo de calzoncillos.
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab Hydantoin derivatives used as mmp12 inhibitors
US20100262110A1 (en) 2007-11-14 2010-10-14 Sca Hygiene Products Ab Method of producing an absorbent garment, and an absorbent garment produced according to the method
BRPI0722260A2 (pt) 2007-11-14 2014-04-01 Sca Hygiene Prod Ab Método de produção de um vestuário absorvente, e um vestuário absorvente produzido de acordo com o método
FR2927330B1 (fr) * 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
JP5539965B2 (ja) 2008-04-28 2014-07-02 レバレジオ コーポレイション 多発性硬化症を治療するための組成物および方法
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
WO2010126030A1 (ja) * 2009-04-28 2010-11-04 中外製薬株式会社 スピロイミダゾロン誘導体
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011054734A1 (de) * 2009-11-06 2011-05-12 Basf Se Eisen- und manganhaltiger heterogenkatalysator und verfahren zur herstellung von olefinen durch umsetzung von kohlenmonoxid mit wasserstoff
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
BR112015004637B1 (pt) * 2012-09-04 2022-04-05 Shanghai Hengrui Pharmaceutical Co., Ltd. Derivados de imidazolina, seus usos e seus processos de preparação, e composição farmacêutica
JP5951799B2 (ja) 2012-12-10 2016-07-13 中外製薬株式会社 ヒダントイン誘導体
WO2015071534A1 (en) * 2013-11-13 2015-05-21 Hankkija Oy A feed supplement and a feed composition comprising resin acid based composition
EP3089975B1 (en) * 2013-12-31 2018-06-06 Ipsen Pharma S.A.S. Novel imidazolidine-2, 4-dione derivatives
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
CN106572994B (zh) * 2014-06-09 2020-09-18 中外制药株式会社 含有乙内酰脲衍生物的药物组合物
PL3209655T3 (pl) 2014-10-24 2020-12-28 Landos Biopharma, Inc. Leczenie oparte na białku 2 podobnym do syntetazy lantioniny C
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
CN109803961B (zh) * 2016-09-23 2021-03-23 科研制药株式会社 (r)-5-(3,4-二氟苯基)-5-[(3-甲基-2-氧代吡啶-1(2h)-基)甲基]咪唑烷-2,4-二酮的制造方法及用于该制造的中间体
WO2021011723A1 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis hydantoin compounds and related compositions and methods
CN115667227A (zh) * 2019-11-14 2023-01-31 逸达生物科技股份有限公司 基质金属蛋白酶(mmp)抑制剂及其使用方法
JP7430852B2 (ja) 2019-12-20 2024-02-14 エヌイミューン バイオファーマ インコーポレイテッド ランチオニンｃ様タンパク質２リガンド、それを用いて調製される細胞、およびそれを使用する療法
JP2023533462A (ja) 2020-06-26 2023-08-03 ザ ユニバーシティ オブ バーミンガム 脊髄損傷または関連する神経組織の損傷を治療するためのｍｍｐ－９及びｍｍｐ－１２の阻害
WO2022007866A1 (zh) * 2020-07-09 2022-01-13 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用
CN112574193B (zh) * 2020-12-31 2022-05-17 南京医科大学 一类口服gsnor抑制剂及其药物用途

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) * 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
CS152617B1 (hu) 1970-12-29 1974-02-22
CS151744B1 (hu) 1971-01-19 1973-11-19
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
JPH0279879A (ja) 1988-09-17 1990-03-20 Canon Inc 画像形成装置
US4983771A (en) 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
JPH07105549A (ja) 1993-09-30 1995-04-21 Canon Inc 光学的情報記録再生方法及び光学的情報記録再生装置
AU687953B2 (en) 1993-11-16 1998-03-05 Merck & Co., Inc. Piperidinylcamphorsulfonyl oxytocin antagonists
ATE183184T1 (de) 1994-01-31 1999-08-15 Pfizer Neuroprotektive chroman verbindungen
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
CZ291337B6 (cs) * 1995-11-22 2003-02-12 Darwin Discovery Limited Merkaptoalkylpeptidylová sloučenina, její použití pro výrobu přípravku pro léčení nebo prevenci stavu souvisejícího s metalloproteinázou nebo TNFalfa a farmaceutický přípravek ji obsahující
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
ES2171905T3 (es) * 1996-10-22 2002-09-16 Upjohn Co Acidos alfa-amino sulfonilo hidroxamicos como inhibidores de metaloproteinasa de matriz.
EP0983239A1 (en) * 1997-05-06 2000-03-08 Novo Nordisk A/S Novel heterocyclic compounds
DK0877019T3 (da) 1997-05-09 2002-04-08 Hoechst Ag Substituerede diaminocarboxylsyrer
JP2002504916A (ja) 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1178906C (zh) * 1997-07-31 2004-12-08 艾博特公司 基质金属蛋白酶的逆异羟肟酸盐抑制剂
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
BR9814147A (pt) * 1997-11-12 2000-10-03 Darwin Discovery Ltd "derivados de ácido carboxìlico e hidroxâmico tendo atividade inibitória de mmp e tnf"
HUP0101176A3 (en) * 1998-02-04 2002-06-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
WO1999058528A1 (en) * 1998-05-14 1999-11-18 Bristol-Myers Squibb Pharma Company. Substituted aryl hydroxamic acids as metalloproteinase inhibitors
CN1295561A (zh) * 1998-06-03 2001-05-16 Gpinil控股公司 N－杂环羧酸或羧酸等排物的n－结合氨磺酰
EP1087937A1 (en) 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2782082B3 (fr) 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
JP2000127349A (ja) * 1998-08-21 2000-05-09 Komori Corp 凹版印刷機
EP1107953A1 (en) 1998-08-29 2001-06-20 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
EP1117616B1 (en) 1998-10-07 2003-04-23 Yazaki Corporation Sol-gel process using porous mold
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
CZ20012006A3 (cs) 1998-12-18 2002-03-13 Axys Pharmaceuticals, Inc. Sloučenina a farmaceutický prostředek
AU1817700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
EP1149843A4 (en) 1999-01-28 2012-06-06 Chugai Pharmaceutical Co Ltd SUBSTITUTED PHENETHYLAMINE DERIVATIVES
US6294694B1 (en) 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US20020006920A1 (en) * 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
US6266453B1 (en) 1999-07-26 2001-07-24 Computerized Medical Systems, Inc. Automated image fusion/alignment system and method
ES2258431T3 (es) * 1999-08-02 2006-09-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de benzotiofeno.
YU9602A (sh) 1999-08-12 2004-11-25 Pharmacia Italia S.P.A. Derivati 3(5)-amino-pirazola, postupak za njihovu izradu i njihova upotreba kao antitumornih agenasa
JP3710964B2 (ja) 1999-08-26 2005-10-26 富士通株式会社 ディスプレイデバイスのレイアウト設計方法
SE9904044D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US7335673B2 (en) 2000-08-11 2008-02-26 Kaken Pharmaceutical Co., Ltd. 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
US20020065219A1 (en) * 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
WO2002020515A1 (en) 2000-09-08 2002-03-14 Abbott Laboratories Oxazolidinone antibacterial agents
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
EP1191024A1 (en) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
MXPA03008180A (es) 2001-03-15 2003-12-12 Astrazeneca Ab Inhibidores de metaloproteinasa.
JP2004535411A (ja) * 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
KR20050010826A (ko) 2002-06-05 2005-01-28 가부시키가이샤 가네카 광학 활성 α-메틸시스테인 유도체의 제조 방법
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
SE0202693D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6890913B2 (en) * 2003-02-26 2005-05-10 Food Industry Research And Development Institute Chitosans
US20040266832A1 (en) 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
SE0401763D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
SK10922003A3 (sk) 2004-05-04
KR20030082989A (ko) 2003-10-23
RU2293729C2 (ru) 2007-02-20
RU2003127734A (ru) 2005-03-20
US20080306065A1 (en) 2008-12-11
JP2004523583A (ja) 2004-08-05
ATE333454T1 (de) 2006-08-15
PL365099A1 (en) 2004-12-27
WO2002074748A1 (en) 2002-09-26
PL364707A1 (en) 2004-12-13
EP1676846B1 (en) 2010-12-29
CN1304377C (zh) 2007-03-14
CN1509272A (zh) 2004-06-30
KR20030082986A (ko) 2003-10-23
EE200300445A (et) 2003-12-15
US7427631B2 (en) 2008-09-23
CN100526307C (zh) 2009-08-12
US8153673B2 (en) 2012-04-10
IL157656A (en) 2010-11-30
US20080262045A1 (en) 2008-10-23
WO2002074767A8 (en) 2004-04-22
US20100273849A1 (en) 2010-10-28
HK1060121A1 (en) 2004-07-30
US20080171882A1 (en) 2008-07-17
US20040106659A1 (en) 2004-06-03
SK287834B6 (sk) 2011-12-05
NZ528106A (en) 2005-03-24
SK287766B6 (sk) 2011-09-05
EP1370556B1 (en) 2006-07-19
IS6942A (is) 2003-09-09
PT1370556E (pt) 2006-11-30
JP2010077137A (ja) 2010-04-08
KR20030082987A (ko) 2003-10-23
HUP0400202A3 (en) 2004-10-28
HUP0400194A3 (en) 2004-10-28
EE200300451A (et) 2003-12-15
WO2002074748A8 (en) 2004-04-22
JP5140058B2 (ja) 2013-02-06
DE60213216D1 (en) 2006-08-31
ES2352246T3 (es) 2011-02-16
EP1370556A1 (en) 2003-12-17
IL157656A0 (en) 2004-03-28
ZA200306734B (en) 2004-11-29
NO20034042L (no) 2003-11-10
SE0100902D0 (sv) 2001-03-15
WO2002074767A1 (en) 2002-09-26
US7368465B2 (en) 2008-05-06
NO20034045L (no) 2003-11-10
KR20080071210A (ko) 2008-08-01
EP1676846A2 (en) 2006-07-05
EP1370534A1 (en) 2003-12-17
NO20034042D0 (no) 2003-09-12
EP1370537A1 (en) 2003-12-17
IS6946A (is) 2003-09-10
SK10962003A3 (sk) 2004-03-02
MXPA03008181A (es) 2003-12-12
HUP0400327A3 (en) 2005-06-28
SI1370556T1 (sl) 2006-10-31
CY1107525T1 (el) 2013-03-13
IS6943A (is) 2003-09-09
SK10952003A3 (sk) 2004-05-04
EE200300449A (et) 2003-12-15
CZ20032499A3 (cs) 2004-03-17
UA77667C2 (en) 2007-01-15
UA78502C2 (en) 2007-04-10
CN1962641A (zh) 2007-05-16
CN1269804C (zh) 2006-08-16
CA2440630A1 (en) 2002-09-26
KR100886315B1 (ko) 2009-03-04
CZ20032500A3 (cs) 2004-02-18
CZ20032497A3 (cs) 2004-02-18
DE60238794D1 (de) 2011-02-10
AR035695A1 (es) 2004-06-23
US20040127528A1 (en) 2004-07-01
EE05364B1 (et) 2010-12-15
CA2440630C (en) 2011-09-27
ES2267986T3 (es) 2007-03-16
ZA200306737B (en) 2004-11-29
UA77408C2 (en) 2006-12-15
RU2003127733A (ru) 2005-03-20
ES2357138T3 (es) 2011-04-19
DE60237965D1 (en) 2010-11-25
CN1509276A (zh) 2004-06-30
BR0207984A (pt) 2004-06-15
CA2440631A1 (en) 2002-09-26
JP2004523581A (ja) 2004-08-05
NO327114B1 (no) 2009-04-27
MXPA03008177A (es) 2003-12-12
ATE493406T1 (de) 2011-01-15
CA2440473C (en) 2011-08-30
DE60213216T2 (de) 2007-07-12
AU2002237632B2 (en) 2007-05-10
IL157652A (en) 2010-11-30
HK1059932A1 (en) 2004-07-23
NO20034045D0 (no) 2003-09-12
IL157652A0 (en) 2004-03-28
US7754750B2 (en) 2010-07-13
RU2288228C2 (ru) 2006-11-27
PL364706A1 (en) 2004-12-13
HUP0400202A2 (hu) 2004-08-30
CN101602731A (zh) 2009-12-16
MY136141A (en) 2008-08-29
WO2002074751A1 (en) 2002-09-26
BR0207983A (pt) 2004-06-15
ZA200306732B (en) 2004-11-29
US7625934B2 (en) 2009-12-01
HUP0400194A2 (hu) 2004-07-28
ZA200306731B (en) 2004-11-29
MXPA03008191A (es) 2004-01-29
MY136789A (en) 2008-11-28
RU2285695C2 (ru) 2006-10-20
AU2002237626B2 (en) 2007-05-17
CA2440473A1 (en) 2002-09-26
CN1509286A (zh) 2004-06-30
EE05431B1 (et) 2011-06-15
NZ528140A (en) 2005-02-25
RU2003127735A (ru) 2005-03-20
JP2004527515A (ja) 2004-09-09
PL205315B1 (pl) 2010-04-30
NO20034044L (no) 2003-11-10
NO326087B1 (no) 2008-09-15
EP1370537B1 (en) 2010-10-13
NZ528107A (en) 2005-06-24
EP1676846A3 (en) 2006-07-26
IL157657A0 (en) 2004-03-28
BR0208104A (pt) 2004-03-02
NO20034044D0 (no) 2003-09-12
KR100879905B1 (ko) 2009-01-21
CN1962641B (zh) 2012-07-04
HK1091492A1 (en) 2007-01-19
JP4390457B2 (ja) 2009-12-24
US20040138276A1 (en) 2004-07-15
ATE484496T1 (de) 2010-10-15
AR035443A1 (es) 2004-05-26
HUP0400327A2 (hu) 2005-01-28
US20110003853A1 (en) 2011-01-06
US7666892B2 (en) 2010-02-23

Similar Documents

Publication Publication Date Title
DK1370556T3 (da) Metalloproteinaseinhibitorer
NO20034025L (no) Metalloproteinaseinhibitorer
NO20034027D0 (no) Metalloproteinaseinhibitorer
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE50103741D1 (de) Welle-Nabe-Verbindung
ATE335486T1 (de) Hydrazono-malonitrile
DE1319930T1 (de) Coriolismassendurchflussmesser
DE50203412D1 (de) Schwenkkolbenverdränger
ATE355059T1 (de) Isoxazolopyridinone
DE50201862D1 (de) Messwandler
DE50203093D1 (de) Losradlager
ATE319694T1 (de) Phenylalkyne
ATA18372001A (de) Gelenksbolzenbaueinheit
DE50202088D1 (de) Garmodulsystem
DE50108381D1 (de) Synchronisierschaltungsanordnung
DE10295006D2 (de) Bauwerksabdichtung
ATA13992002A (de) Schlackengranulierungsanlage
AT500276B1 (de) Radschwenksystem
ATE345337T1 (de) Delta1 -pyrroline
ATA7462001A (de) Radspannwerk
DE10196706D2 (de) Nagelfeile
DE10295832D2 (de) Dioxathianone
DE10142202B8 (de) Hochvakuumbedampfungsanlage
ATA6162001A (de) Schneekette
DE10295829D2 (de) Furanonsyntese